Progress in the research and application of tumor markers for gallbladder cancer

doi:10.3877/cma.j.issn.1674-0793.2023.05.015

Abstract

Abstract:

Gallbladder cancer is highly malignant, aggressive and shows poor prognosis. Only part of patients with gallbladder cancer can receive radical surgery. In recent years, the research on tumor markers has developed rapidly, and the exploration of new therapeutic targets and tumor related markers has provided great assistance for the detection, diagnosis and treatment of gallbladder cancer. At the same time, with the advancement of liquid biopsy, gene sequencing and other technologies, the application scope of tumor markers have been broadened, and targeted combination immunotherapy has become a new treatment method for gallbladder cancer, laying the foundation for the precision medicine of gallbladder cancer.

Key words: Gallbladder carcinoma, Tumor marker, Targeted therapy, Immunotherapy, Precision medicine

Jia Yan, Shuangchi Liu, Zhengyu Wang. Progress in the research and application of tumor markers for gallbladder cancer[J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(05): 391-394.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2023.05.015

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2023/V17/I05/391

References 21

[1]	Christensen TD, Maag E, Larsen O, et al. Development and validation of circulating protein signatures as diagnostic biomarkers for biliary tract cancer[J]. JHEP Rep, 2023, 5(3): 100648.
[2]	Sinha SR, Prakash P, Singh RK, et al. Assessment of tumor markers CA19-9, CEA, CA125, and CA242 for the early diagnosis and prognosis prediction of gallbladder cancer[J]. World J Gastrointest Surg, 2022, 14(11): 1272-1284.
[3]	Yin BW, Dnistrian A, Lloyd KO. Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene[J]. Int J Cancer, 2002, 98(5): 737-740.
[4]	段海章, 陈进忠, 石岩, 等. MUC1和MUC16在胆囊癌中的表达及临床意义[J]. 现代肿瘤医学, 2018, 26(18): 2892-2896.
[5]	Carrasco C, Tittarelli A, Paillaleve N, et al. The evaluation of 17 gastrointestinal tumor markers reveals prognosis value for MUC6, CK17, and CD10 in gallbladder-cancer patients[J]. Diagnostics (Basel), 2021, 11(2): 153.
[6]	He Y, Xue C, Yu Y, et al. CD44 is overexpressed and correlated with tumor progression in gallbladder cancer[J]. Cancer Manag Res, 2018, 10: 3857-3865.
[7]	Goodall GJ, Wickramasinghe VO. RNA in cancer[J]. Nat Rev Cancer, 2021, 21(1): 22-36.
[8]	Liu N, Chang CW, Steer CJ, et al. MicroRNA-15a/16-1 prevents hepatocellular carcinoma by disrupting the communication between Kupffer cells and regulatory T cells[J]. Gastroenterology, 2022, 162(2): 575-589.
[9]	Yan X, Yang P, Liu H, et al. miR-4461 inhibits the progression of gallbladder carcinoma via regulating EGFR/AKT signaling[J]. Cell Cycle, 2022, 21(11): 1166-1177.
[10]	Hu X, Zhang J, Bu J, et al. MiR-4733-5p promotes gallbladder carcinoma progression via directly targeting Kruppel like factor 7[J]. Bioengineered, 2022, 13(4): 10691-10706.
[11]	Huang X, He M, Huang S, et al. Circular RNA circERBB2 promotes gallbladder cancer progression by regulating PA2G4-dependent rDNA transcription[J]. Mol Cancer, 2019, 18(1): 166.
[12]	Zhang N, Li J, Sun H, et al. Circ_0008234 regulates the biological process of gallbladder carcinoma by targeting the miR-204-5p/FGFR2 axis[J]. Histol Histopathol, 2022: 18538.
[13]	Wang S, Zhang Y, Cai Q, et al. Circular RNA FOXP1 promotes tumor progression and Warburg effect in gallbladder cancer by regulating PKLR expression[J]. Mol Cancer, 2019, 18(1): 145.
[14]	Hu YP, Jin YP, Wu XS, et al. LncRNA-HGBC stabilized by HuR promotes gallbladder cancer progression by regulating miR-502-3p/SET/AKT axis[J]. Mol Cancer, 2019, 18(1): 167.
[15]	Chen J, Yu Y, Li H, et al. Long non-coding RNA PVT1 promotes tumor progression by regulating the miR-143/HK2 axis in gallbladder cancer[J]. Mol Cancer, 2019, 18(1): 33.
[16]	Shen N, Zhang D, Yin L, et al. Bile cell-free DNA as a novel and powerful liquid biopsy for detecting somatic variants in biliary tract cancer[J]. Oncol Rep, 2019, 42(2): 549-560.
[17]	Yang P, Song F, Yang X, et al. Exosomal microRNA signature acts as an efficient biomarker for non-invasive diagnosis of gallbladder carcinoma[J]. iScience, 2022, 25(9): 104816.
[18]	张一鉴, 刘颖斌. Journal of Hepatology\|利用单细胞RNA测序发现在ErbB通路突变的胆囊癌中存在MDK依赖免疫抑制微环境[J]. 临床肝胆病杂志, 2022, 38(2): 281.
[19]	Li M, Liu F, Zhang F, et al. Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: A whole-exome sequencing analysis[J]. Gut, 2019, 68(6): 1024-1033.
[20]	Yang M, Zhao Y, Li Y, et al. Afatinib in combination with GEMOX chemotherapy as the adjuvant treatment in patients with ErbB pathway mutated, resectable gallbladder cancer: study protocol for a ctDNA-based, multicentre, open-label, randomised, controlled, phase Ⅱ trial[J]. BMJ Open, 2023, 13(2): e061892.
[21]	Chen X, Wang D, Liu J, et al. Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes[J]. J Immunother Cancer, 2021, 9(11): e003214.

Please choose a citation manager

Content to export